SCHEMBL25524949

SCHEMBL25524949

CCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@@H]1C[C@@H](O)CN1)C(C)CC)C(=O)O

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ F2 P00734 4/20 0.45
▸ MAPK8 P45983 1/20 0.44
▸ MAPK9 P45984 1/20 0.44
▸ MAPK10 P53779 1/20 0.44
▸ KEAP1 Q14145 1/20 0.44
▸ NPY2R P49146 6/20 0.43
▸ NPY4R P50391 6/20 0.43
▸ NPY5R Q15761 6/20 0.43
▸ NPY1R P25929 4/20 0.43
▸ NTSR1 P30989 2/20 0.43
▸ HCRTR1 O43613 1/20 0.43
▸ HCRTR2 O43614 1/20 0.43
▸ CALCR P30988 1/20 0.43
▸ GLP1R P43220 1/20 0.42
▸ GCGR P47871 1/20 0.42
▸ GIPR P48546 1/20 0.42
▸ NTSR2 O95665 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22018328 0.96 NPY2R (0.47) F2NPY2RNPY4RNPY5RNPY1R
SCHEMBL25524938 0.96 APLNR (0.44) F2NPY2RNPY4RNPY5RNPY1R
SCHEMBL22019477 0.95 NPY2R (0.44) NPY2RNPY4RNPY5RNPY1RCALCR
SCHEMBL25524960 0.95 RAMP3 (0.46) MAPK8MAPK9MAPK10KEAP1NPY2R
SCHEMBL25524928 0.95 APLNR (0.45) F2NPY2RNPY4RNPY5RNPY1R
SCHEMBL25524962 0.94 NMUR2 (0.46) F2NPY2RNPY4RNPY5RNPY1R
SCHEMBL22018499 0.92 NTSR1 (0.45) MAPK8MAPK9MAPK10NPY2RNPY4R
SCHEMBL22018329 0.92 NPY2R (0.47) NPY2RNPY4RNPY5RNPY1RGLP1R
SCHEMBL29308344 0.91 OPRD1 (0.43) F2NPY2RNPY4RNPY5RNPY1R
SCHEMBL22018604 0.91 APLNR (0.45) NPY2RNPY4RNPY5RNPY1RHCRTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230146455-A1 TREATMENT OF INFLAMMATORY DISEASES WITH PEPTIDES AND PHARMACEUTICAL COMPOSITIONS YUYU PHARMA, INC. (KR) 2023-05-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230146455-A1 TREATMENT OF INFLAMMATORY DISEASES WITH PEPTIDES AND PHARMACEUTICAL COMPOSITIONS VIP, TSLP, IAPP F2 780/4885MAPK8 2755/4885MAPK9 2634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback